top of page


FDA approves Roche's Wilserdly with everolimus for ESR1-mutated advanced breast cancer
Roche's oral selective oestrogen receptor degrader Wilserdly has received FDA approval alongside everolimus for eligible patients with ESR1-mutated advanced breast cancer, supported by Phase III evidence of reduced disease progression risk.

nuaxia
6 hours ago2 min read


Agilent completes Proscia acquisition for $240 million upfront to expand AI-enabled digital pathology
Agilent Technologies has completed its acquisition of Proscia for $240 million upfront, adding digital-pathology software and AI-enabled diagnostic capabilities to its life sciences and diagnostics business.

nuaxia
Nov 62 min read


FDA approves Labcorp PGDx elio tissue complete CDx for BRAF-targeted therapy selection in advanced melanoma
The next-generation sequencing companion diagnostic identifies BRAF V600E and V600K variants, helping clinicians determine which melanoma patients may be eligible for FDA-approved BRAF or BRAF/MEK targeted therapies.

nuaxia
Aug 112 min read
bottom of page